FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.

ABSTRACT:

Unlabelled

Daily teriparatide injections have been shown to reduce vertebral and non-vertebral fractures. Here, we demonstrate that the magnitude of fracture risk reduction is independent of baseline fracture probability assessed by FRAX.

Introduction

Daily administration of 20 or 40 μg teriparatide has been shown to significantly decrease the risk of vertebral and non-vertebral fracture compared with placebo. The aim of the present study was to evaluate fracture risk assessed at baseline using the FRAX® tool and to determine the efficacy of teriparatide as a function of baseline fracture risk.

Methods

One thousand six hundred thirty-seven postmenopausal women in the pivotal phase three trial, randomly assigned to receive placebo (n = 544), teriparatide 20 μg per day

SUBMITTER: Harvey NC 

PROVIDER: S-EPMC4913866 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature